Table 2– Response of brain metastases in patients treated with erlotinib
All patientsCases with EGFR mutationsControl cases
Patients n531736
CR8 (15.1)8 (47.1)0
PR6 (11.3)6 (35.3)0
CR+PR14 (26.4)14 (82.4)0
SD31 (58.5)3 (7.6)28 (77.8)
PD8 (15.3)08 (22.2)
  • Data are presented as n (%), unless otherwise stated. Data for the entire series, for those patients harbouring EGFR gene mutations and for control cases are shown. EGFR: epidermal growth factor receptor; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.